Drisapersen
Muscular Dystrophies
GlaxoSmithKlinenucleic_acidPhase 3Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 29/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Muscular Dystrophies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gsk2402968 GlaxoSmithKline | Phase 3 | BB |
Ataluren PTC Therapeutics | Phase 3 | B |
Aoc 1044 Avidity Biosciences, Inc. | Phase 3 | B |
Deramiocel Capricor Inc. | Phase 3 | B |
Tadalafil University of Florida | Phase 2 | B |
View all 11 →
Same molecule, other indications
Drisapersen is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →